Bradstreet et al. proposed spironolactone for autistic disorders, and metformin was considered in the treatment of autistic disorders and for depression an involvement of the CRH–ACTH system was implied (Gold 2015; Checkley 1996; Bradstreet et al. 2006; Wink et al. 2017; Aman et al. 2018). The gene discussed is POMC; the disease is depressive symptom measurement.